Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200260007> ?p ?o ?g. }
Showing items 1 to 59 of
59
with 100 items per page.
- W4200260007 abstract "Purpose: To determine recurrence and retreatment patterns after treatment of severe retinopathy of Prematurity (ROP) with either 0.5 mg, 0.25 mg, or 0.125 mg of intravitreal bevacizumab for retinopathy of prematurity.
 Methods: In this retrospective chart review, data was examined for babies who had severe ROP and were treated with intravitreal bevacizumab doses of either 0.500 mg, 0.250 mg, or 0.125 mg at Riley Hospital for Children in Indianapolis from 2014 to 2021. Data collected included demographic information, past medical history, and characteristics of ROP. The data was statistically analyzed using SPSS software.
 Results: One eye was analyzed for each baby. Out of 85 babies, 79 babies were included in the study. 26 babies were treated with 0.125 mg bevacizumab, 37 with 0.25 mg, and 16 with 0.5 mg. All babies showed initial response to the bevacizumab, with 61 babies (77.2%) receiving retreatment with laser for either recurrence or persistent avascular retina. While the babies treated with lower doses had higher percentages of retreatment (23 babies (88.5%) in the 0.125 mg, 29 babies (78.4%) in the 0.25 mg, and 9 babies (56.3%) in the 0.5 mg group), the difference was not statistically significant (p=0.069). Most of the retreatments were due to recurrence of ROP (0.125 mg: 20 (87.0%), 0.25 mg: 19 (65.5%), 0.50 mg: 8 (88.9%)) (p=0.339). On average, the babies in the 0.125 mg group were retreated with laser at 3.4 weeks earlier gestational age and 4.7 weeks sooner after initial treatment than the higher dosing groups, however, this difference was not statistically significant (p=0.181, p=0.287).
 Conclusion: The outcomes comparing three doses of intravitreal bevacizumab for severe ROP showed a slight variation in recurrence and retreatment patterns but no statistically significant difference in our study." @default.
- W4200260007 created "2021-12-31" @default.
- W4200260007 creator A5046546720 @default.
- W4200260007 creator A5058548715 @default.
- W4200260007 date "2021-12-10" @default.
- W4200260007 modified "2023-09-25" @default.
- W4200260007 title "Comparing Recurrence and Retreatment of Three Doses of Bevacizumab in Treating Severe Retinopathy of Prematurity" @default.
- W4200260007 doi "https://doi.org/10.18060/25899" @default.
- W4200260007 hasPublicationYear "2021" @default.
- W4200260007 type Work @default.
- W4200260007 citedByCount "0" @default.
- W4200260007 crossrefType "journal-article" @default.
- W4200260007 hasAuthorship W4200260007A5046546720 @default.
- W4200260007 hasAuthorship W4200260007A5058548715 @default.
- W4200260007 hasBestOaLocation W42002600071 @default.
- W4200260007 hasConcept C118487528 @default.
- W4200260007 hasConcept C141071460 @default.
- W4200260007 hasConcept C167135981 @default.
- W4200260007 hasConcept C187212893 @default.
- W4200260007 hasConcept C195910791 @default.
- W4200260007 hasConcept C2776694085 @default.
- W4200260007 hasConcept C2777802072 @default.
- W4200260007 hasConcept C2778376644 @default.
- W4200260007 hasConcept C2779234561 @default.
- W4200260007 hasConcept C2779918416 @default.
- W4200260007 hasConcept C54355233 @default.
- W4200260007 hasConcept C71924100 @default.
- W4200260007 hasConcept C86803240 @default.
- W4200260007 hasConceptScore W4200260007C118487528 @default.
- W4200260007 hasConceptScore W4200260007C141071460 @default.
- W4200260007 hasConceptScore W4200260007C167135981 @default.
- W4200260007 hasConceptScore W4200260007C187212893 @default.
- W4200260007 hasConceptScore W4200260007C195910791 @default.
- W4200260007 hasConceptScore W4200260007C2776694085 @default.
- W4200260007 hasConceptScore W4200260007C2777802072 @default.
- W4200260007 hasConceptScore W4200260007C2778376644 @default.
- W4200260007 hasConceptScore W4200260007C2779234561 @default.
- W4200260007 hasConceptScore W4200260007C2779918416 @default.
- W4200260007 hasConceptScore W4200260007C54355233 @default.
- W4200260007 hasConceptScore W4200260007C71924100 @default.
- W4200260007 hasConceptScore W4200260007C86803240 @default.
- W4200260007 hasIssue "1" @default.
- W4200260007 hasLocation W42002600071 @default.
- W4200260007 hasOpenAccess W4200260007 @default.
- W4200260007 hasPrimaryLocation W42002600071 @default.
- W4200260007 hasRelatedWork W1969249427 @default.
- W4200260007 hasRelatedWork W2083293189 @default.
- W4200260007 hasRelatedWork W2502072298 @default.
- W4200260007 hasRelatedWork W2772345009 @default.
- W4200260007 hasRelatedWork W2891187125 @default.
- W4200260007 hasRelatedWork W3029407746 @default.
- W4200260007 hasRelatedWork W3087669720 @default.
- W4200260007 hasRelatedWork W4200164386 @default.
- W4200260007 hasRelatedWork W4298701792 @default.
- W4200260007 hasRelatedWork W948362459 @default.
- W4200260007 hasVolume "4" @default.
- W4200260007 isParatext "false" @default.
- W4200260007 isRetracted "false" @default.
- W4200260007 workType "article" @default.